|
1
|
Bosman FT; World Health Organization and
International Agency for Research on Cancer: WHO Classification of
Tumours of the Digestive System. IARC Press; Lyon: 2010
|
|
2
|
Lampejo T, Kavanagh D, Clark J, Goldin R,
Osborn M, Ziprin P and Cleator S: Prognostic biomarkers in squamous
cell carcinoma of the anus: A systematic review. Br J Cancer.
103:1858–1869. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rousseau DL Jr, Thomas CR Jr, Petrelli NJ
and Kahlenberg MS: Squamous cell carcinoma of the anal canal. Surg
Oncol. 14:121–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leonard D, Beddy D and Dozois EJ:
Neoplasms of anal canal and perianal skin. Clin Colon Rectal Surg.
24:54–63. 2011. View Article : Google Scholar :
|
|
6
|
Deans GT, McAleer JJ and Spence RA:
Malignant anal tumours. Br J Surg. 81:500–508. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Franklin RA, Giri S, Valasareddy P, Lands
LT and Martin MG: Comparative survival of patients with anal
adenocarcinoma, squamous cell carcinoma of the anus, and rectal
adenocarcinoma. Clin Colorectal Cancer. 15:47–53. 2016. View Article : Google Scholar
|
|
8
|
Franceschi S and De Vuyst H: Human
papillomavirus vaccines and anal carcinoma. Curr Opin HIV AIDS.
4:57–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Serup-Hansen E, Linnemann D,
Skovrider-Ruminski W, Høgdall E, Geertsen PF and Havsteen H: Human
papillo-mavirus genotyping and p16 expression as prognostic factors
for patients with American joint committee on cancer stages I to
III carcinoma of the anal canal. J Clin Oncol. 32:1812–1817. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Doorbar J: Molecular biology of human
papillomavirus infection and cervical cancer. Clin Sci (Lond).
110:525–541. 2006. View Article : Google Scholar
|
|
11
|
Veo CA, Saad SS, Fregnani JH,
Scapulatempo-Neto C, Tsunoda AT, Resende JC, Lorenzi AT, Mafra A,
Cinti C, Cotrim ID, et al: Clinical characteristics of women
diagnosed with carcinoma who tested positive for cervical and anal
high-risk human papillomavirus DNA and E6 RNA. Tumour Biol.
36:5399–5405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mai S, Welzel G, Ottstadt M, Lohr F,
Severa S, Prigge ES, Wentzensen N, Trunk MJ, Wenz F, von
Knebel-Doeberitz M and Reuschenbach M: Prognostic relevance of HPV
infection and p16 overexpression in squamous cell anal cancer. Int
J Radiat Oncol Biol Phys. 93:819–827. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meulendijks D, Tomasoa NB, Dewit L, Smits
PH, Bakker R, van Velthuysen ML, Rosenberg EH, Beijnen JH,
Schellens JH and Cats A: HPV-negative squamous cell carcinoma of
the anal canal is unresponsive to standard treatment and frequently
carries disruptive mutations in TP53. Br J Cancer. 112:1358–1366.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smaglo BG, Tesfaye A, Halfdanarson TR,
Meyer JE, Wang J, Gatalica Z, Reddy S, Arguello D and Boland PM:
Comprehensive multiplatform biomarker analysis of 199 anal squamous
cell carcinomas. Oncotarget. 6:43594–43604. 2015.PubMed/NCBI
|
|
15
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the effcacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Scapulatempo-Neto C, Veo CA, Fregnani JH,
Lorenzi A, Mafra A, Melani A, Loaiza E, Rosa L, de Oliveira C, Levi
J and Longatto-Filhø A: Characterization of topoisomerase II alpha
(TOP2A) and minichromosome maintenance protein (MCM)2 expression in
anal carcinoma. Oncol Lett. 2016.
|
|
17
|
Yamane LS, Scapulatempo-Neto C, Alvarenga
L, Oliveira CZ, Berardinelli GN, Almodova E, Cunha TR, Fava G,
Colaiacovo W, Melani A, et al: KRAS and BRAF mutations and MSI
status in precursor lesions of colorectal cancer detected by
colonoscopy. Oncol Rep. 32:1419–1426. 2014.PubMed/NCBI
|
|
18
|
Matalon SA, Mamon HJ, Fuchs CS, Doyle LA,
Tirumani SH, Ramaiya NH and Rosenthal MH: Anorectal cancer:
Critical anatomic and staging distinctions that affect use of
radiation therapy. Radiographics. 35:2090–2107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ta n C and Du X: KRAS mutation testing in
metastatic colorectal cancer. World J Gastroenterol. 18:5171–5180.
2012.
|
|
20
|
Gil Ferreira C, Aran V, Zalcberg-Renault
I, Victorino AP, Salem JH, Bonamino MH, Vieira FM and Zalis M: KRAS
mutations: Variable incidences in a Brazilian cohort of 8,234
metastatic colorectal cancer patients. BMC Gastroenterol.
14:732014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Okumura S and Jänne PA: Molecular
pathways: The basis for rational combination using MEK inhibitors
in KRAS-mutant cancers. Clin Cancer Res. 20:4193–4199. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gilbert DC, Williams A, Allan K, Stokoe J,
Jackson T, Linsdall S, Bailey CM and Summers J: p16INK4A, p53, EGFR
expression and KRAS mutation status in squamous cell cancers of the
anus: Correlation with outcomes following chemo-radiotherapy.
Radiother Oncol. 109:146–151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paliga A, Onerheim R, Gologan A, Chong G,
Spatz A, Niazi T, Garant A, Macheto D, Alcindor T and Vuong T: EGFR
and K-ras gene mutation status in squamous cell anal carcinoma: A
role for concurrent radiation and EGFR inhibitors? Br J Cancer.
107:1864–1868. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Casadei Gardini A, Capelli L, Ulivi P,
Giannini M, Freier E, Tamberi S, Scarpi E, Passardi A, Zoli W,
Ragazzini A, et al: KRAS, BRAF and PIK3CA status in squamous cell
anal carcinoma (SCAC). PLoS One. 9:e920712014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prigge ES, Urban K, Stiegler S, Müller M,
Kloor M, Mai S, Ottstadt M, Lohr F, Wenz F, Wagner S, et al: No
evidence of oncogenic KRAS mutations in squamous cell carcinomas of
the anogenital tract and head and neck region independent of human
papillomavirus and p16 (INK4a) status. Hum Pathol. 45:2347–2354.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Serup-Hansen E, Linnemann D, Høgdall E,
Geertsen PF and Havsteen H: KRAS and BRAF mutations in anal
carcinoma. APMIS. 123:53–59. 2015. View Article : Google Scholar
|
|
27
|
Martin V, Zanellato E, Franzetti-Pellanda
A, Molinari F, Movilia A, Paganotti A, Deantonio L, De Dosso S,
Assi A, Crippa S, et al: EGFR, KRAS, BRAF, and PIK3CA
characterization in squamous cell anal cancer. Histol Histopathol.
29:513–521. 2014.
|
|
28
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
El-Deiry WS, Vijayvergia N, Xiu J,
Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z and Reddy S:
Molecular profiling of 6,892 colorectal cancer samples suggests
different possible treatment options specific to metastatic sites.
Cancer Biol Ther. 16:1726–1737. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bartelink H, Roelofsen F, Eschwege F,
Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M and
Pierart M: Concomitant radiotherapy and chemotherapy is superior to
radiotherapy alone in the treatment of locally advanced anal
cancer: Results of a phase III randomized trial of the European
Organization for Research and Treatment of Cancer Radiotherapy and
Gastrointestinal Cooperative groups. J Clin Oncol. 15:2040–2049.
1997.PubMed/NCBI
|
|
31
|
Lukan N, Ströbel P, Willer A, Kripp M,
Dinter D, Mai S, Hochhaus A and Hofheinz RD: Cetuximab-based
treatment of metastatic anal cancer: Correlation of response with
KRAS mutational status. Oncology. 77:293–299. 2009. View Article : Google Scholar : PubMed/NCBI
|
